Immune recovery was retrospectively analyzed in a cohort of 41 patients with acute leukemia, myelodysplastic syndrome and nonmalignant diseases, who received αβ T-and B-cell-depleted allografts from haploidentical family donors. Conditioning regimens consisted of fludarabine or clofarabine, thiotepa, melphalan and serotherapy with OKT3 or ATG-Fresenius. Graft manipulation was carried out with anti-TCRαβ and anti-CD19 Abs and immunomagnetic microbeads. The γδ T cells and natural killer cells remained in the grafts. Primary engraftment occurred in 88%, acute GvHD (aGvHD) grades II and III-IV occurred in 10% and 15%, respectively. Immune recovery data were available in 26 patients and comparable after OKT3 (n = 7) or ATG-F (n = 19). Median time to reach 4100 CD3+ cells/μL, 4200 CD19+ cells/μL and 4200 CD56+ cells/μL for the whole group was 13, 127 and 12.5 days, respectively. Compared with a historical control group of patients with CD34+ selected grafts, significantly higher cell numbers were found for CD3+ at days +30 and +90 (267 vs 27 and 397 vs 163 cells/μL), for CD3+4+ at day +30 (58 vs 11 cells/μL) and for CD56+ at day +14 (622 vs 27 cells/μL). The clinical impact of this accelerated immune recovery will be evaluated in an ongoing prospective multicenter trial.
INTRODUCTION
Transplantation of haploidentical stem cells has become an accepted option for pediatric patients and adults with high-risk malignancies who lack a matched related or unrelated donor. 1 In recent years, the majority of pediatric transplant centers chose the CD34+ selection of peripheral stem cells, which allowed minimizing GvHD by effective reduction of T cells in the graft. Together with myeloablative, TBI or busulfan-based conditioning regimens, acceptable hematopoietic engraftment and survival rates have been observed in both adult and pediatric patients with acute leukemia and nonmalignant diseases. 2, 3 However, infectious complications caused by delayed immune recovery were a major reason for transplant-related mortality, and rates between 5 and 37% [4] [5] [6] [7] [8] have been described in pediatric cohorts. To improve the immune recovery, we have established a new T-cell depletion method that removes αβ+ T lymphocytes via a biotinylated antiTcRαβ Ab followed by an anti-biotin Ab conjugated to magnetic microbeads while retaining γδ+ T lymphocytes, natural killer (NK) cells and other cells in the graft. In addition, CD19+ B lymphocytes were concomitantly depleted for the prevention of posttransplant EBV-associated lymphoproliferative disease. The conditioning regimens consisted of fludarabine or clofarabine, thiotepa, melphalan and serotherapy. Our aim was to reduce the conditioning toxicity without affecting engraftment rates and to accelerate immune recovery. Here, we report immune reconstitution data of a cohort of pilot patients transplanted with this approach.
PATIENTS AND METHODS
We report a retrospective analysis of a cohort of 41 pediatric patients who received TCRαβ/CD19-depleted peripheral allografts after a melphalanbased conditioning with OKT3 or reduced ATG-Fresenius at the Children's University Hospitals Tuebingen (Germany) and Graz (Austria). All donors were ⩾ 2 HLA loci-mismatched parents. A total of 20 patients had ALL, 9 had AML and 3 had advanced myelodysplastic syndrome (MDS) refractory anemia with excess blasts in transmission (RAEB-t) or juvenile myelomonocytic leukemia. Four patients had relapsed solid tumors and five patients had nonmalignant diseases. Of the 36 patients with malignancies, 12 were in first/second and 12 in ⩾ third remission. A total of 12 patients had active disease at the time of stem cell transplantation (SCT), despite additional use of intensified chemotherapies. Twenty-two out of 36 patients (61%) had received one or two previous SCTs and proceeded after salvage chemotherapies to subsequent SCTs within this analysis ( Table 1) .
The αβ+ T and B cells were depleted by using anti-TCRαβ-and anti-CD19-coated microbeads and the automated CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany) as previously described. 9, 10 Treatment protocol Most patients received a myeloablative conditioning regimen consisting of fludarabine (40 mg/m 2 , day − 8 to − 5) or clofarabine (50 mg/m 2 , day − 8 to − 5), thiotepa (2 × 5 mg/kg, day − 4) and melphalan (70 mg/m 2 , day − 3, − 2). OKT3 was given as graft rejection prophylaxis (0.1 mg/kg/ day, maximum dose 5 mg, day − 8 to − 1) in the first seven patients. As OKT3 has not been available since 2012, it was replaced by ATG-Fresenius 15 mg/kg starting on day − 12 (1 mg/kg), − 11 (4 mg/kg), − 10 to − 9 (5 mg/kg each) in the following patients. Methylprednisolone was administered on day − 8 to − 5 (4 mg/kg) and on day − 4 to − 1 (2 mg/kg) 1 to avoid side effects of OKT3. Starting on day 0, hydrocortisone (maximum dose 2 mg/kg) was used to taper steroids until day +11. As part of the antithymocyte globulin (ATG) protocol, methylprednisolone (4 mg/kg) was given on day − 12 to − 9. Short-course mycophenolate mofetil (2 × 600 mg/ m 2 ) was given as prophylactic immune suppression until day +30.
Assessment of GvHD and immune reconstitution
Reconstitution of lymphocyte subsets was monitored weekly by four-color FACS analysis until day +100 followed by an assessment every 3 months. GvHD was graded according to Glucksberg criteria.
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RESULTS
Graft composition
The patients received a median number of 14.9 × 10 6 CD34+ progenitor cells per kg body weight (BW). In addition, grafts contained a median number of 81.3 × 10 6 per kg BW CD56+CD3 − NK cells and 11.0 × 10 6 per kg BW γδ T cells. The median number of residual αβ T cells was 16.9 × 10 3 cells per kg BW (Table 1) .
Clinical outcome Primary engraftment occurred in 36 patients (88%). The median time to an ANC 40.5 × 10 9 /L with G-CSF stimulation was 10 days (range 7-21 days). Five patients (12%) had graft rejection. However, successful engraftment was achieved in all of these patients after reconditioning and subsequent reinfusion of T-and B-cell-depleted progenitors from a different haploidentical donor.
A total of 31 patients (76%) experienced grade 0-1 aGvHD. Four patients had grade 2 aGvHD (10%) and six patients had grade 3 or 4 aGvHD (15%). Extensive chronic GvHD (cGvHD) occurred in 3 out of 32 evaluable patients (9%); limited and transient cGvHD occurred in 6 out of 32 patients (18%) ( Table 1) .
As of March 2014, 21 of the 41 patients are alive, with a median follow-up of 1.6 years. Relapse was the major cause of death (n = 17). Patients with leukemia and MDS who received a first haploidentical SCT in CR1-CR3 showed a favorable 1-year eventfree survival of 100%, whereas no patient with active disease survived. Patients with leukemia/MDS who received a subsequent SCT in CR2-CR6 or with active disease had a 1-year event-free survival of 29% and 11%, respectively. Regeneration of CD3+, CD3+4+ and CD56+ cells of all patients with TCRαβ/CD19 depletion (OKT3 and ATG-Fresenius group) was compared with that of a historical control group of 36 pediatric patients with acute leukemia and MDS transplanted at our institution with positive (CD34+) selected stem cells from haploidentical donors (Figure 2 ). All patients of the control group received myeloablative TBI (12 Gy) or busulfan-based conditioning regimens in combination with serotherapy (OKT3 or ATGFresenius). Patients with TCRαβ/CD19 depletion reached significantly higher counts for CD3+ cells at day +30 and +90 compared to patients with CD34 selection (267 vs 27 cells/μL Abbreviations: BW = body weight; JMML = juvenile myelomonocytic leukemia; NK = natural killer cells; Pat. = patient; RAEB-t = refractory anemia with excess blasts in transmission; SAA = severe aplastic anemia; SCT = stem cell transplantation; MDS = myelodysplastic syndrome. Disease status: degree of remission achieved after chemotherapy before haplo-SCT. Patients with first SCT: these patients were pretreated according to current chemotherapy protocols and received their first SCT within this analysis. Patients with subsequent SCT: these patients had relapsed after previous SCTs and proceeded after salvage chemotherapy to a subsequent (second or third) SCT, carried out within this analysis. Patients were considered evaluable for chronic GvHD, if they engrafted and survived for 100 days. a Median (range).
and 397 vs 163 cells/μL; P o 0.001). CD3+4+ counts were significantly higher at day +30 (58 vs 11 cells/μL; P o0.001). CD56+ counts showed a significant difference at day +14 (622 vs 27 cells/μL; P o 0.05). In the further course of the immune recovery, differences reached no statistical significance any more.
DISCUSSION
In this retrospective analysis, we investigated the immune recovery after transplantation of haploidentical TCRαβ-and CD19-depleted allografts in combination with a melphalanbased less toxic conditioning regimen. In contrast to positive selection of stem cells with CD34-or CD133-coated microbeads, this method directly removes only TCRαβ+ T cells and B cells and retains a variety of leukocyte populations in the graft, such as CD34 − progenitors, TCRγδ+ T cells and NK cells. The αβ T cells can cause severe alloreactivity in the mismatched setting, whereas γδ T cells are supposed to be not involved in classical GvHD. Moreover, γδ T cells can exert graftversus-tumor activity and have anti-infectious properties. 12 The reduction of TCRαβ+ T cells has already been shown to be as effective as in CD34+ selection 9 with only 17 × 10 3 per kg residual cells, whereas a high amount of γδ T cells (11.0 × 10 6 /kg) could be retained in the grafts. Indeed, this co-transfusion of γδ T cells did not result in unexpectedly high markedly increased GvHD II-IV in our patients, as the incidence was comparable to that reported in a large retrospective multicenter analysis of children with ALL who received CD34 selected grafts (25 vs 17% aGvHD II-IV).
The anti-CD3-specific OKT3 Ab was used as rejection prophylaxis until day − 1 without affecting the immune recovery because of its short half-life period. However, owing to its restricted availability, the substance had to be substituted by ATG-Fresenius with a longer half-life period and comprising a broader variety of antigens, with the CD56 antigen in particular. To impair co-transfused NK cells, γδ T cells and posttransplant immune recovery, we established a protocol with reduced ATG doses given at the beginning of the regimen (day − 12 to day − 9). Preliminary results indicate that sufficient serum peak levels of ATG were obtained at day − 8, which provided a rejection prophylaxis with acceptable engraftment rates (87%) and that low ATG levels were reached at day 0, which allowed recoveries of T and NK cells comparable to that after OKT3. Moreover, this approach offers the possibility to avoid posttransplant immunosuppressants or to use short course mycophenolate mofetil with only temporary effects on NK and γδ T cells and thus can provide a basis for further immunotherapies. Because of its low toxicity, even second or subsequent SCTs can be carried out and may be justifiable in this context. Our most important observation was an improved recovery of T and NK cells in the early posttransplant period. Compared with a historical control group of patients with CD34 selected grafts, significantly higher cell numbers were found for CD3+ at days +30 and +90, for CD3+4+ at day +30 and for CD56+ at day +14. We assume that expansion of co-transfused γδ T cells and NK cells (or possibly of committed progenitors) contributed to the early lymphocyte wave. It is remarkable that also αβ T cell recovery was accelerated, despite profound depletion of this subset. The γδ T cells represented the majority of CD3+ cells only until day +30, whereas later on the αβ:γδ T cell ratio normalized. Explanations for this observation might be that a transmission from γδ T cells to αβ T cells occurred or that preceding γδ T cells facilitated αβ T-cell recovery by production of a favorable cytokine environment. In summary, the use of TCRαβ/CD19-depleted stem cells together with a melphalan-based regimen and specifically adjusted serotherapy resulted in a clearly accelerated immune recovery. A currently ongoing prospective multicenter trial has to address the question whether this improved immune recovery will be able to reduce the incidence of severe infections and transplant-related mortality after transplantation. 
